---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007302"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:16:43.076827+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma amends warrants to $0.11 exercise price and removes CEO voting restriction

## Summary
- Reduces exercise price of outstanding Tradeable Warrants to $0.11; Pre-Funded Warrants to $0.001 per share.
- Removes provision that prohibited CEO Dr. Steve N. Slilaty from voting his Series B Preferred Stock.
- Amendment dated October 18, 2023 between Company and Equiniti Trust Company.

## SEC filing metadata
- accession: 0001683168-23-007302
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007302/0001683168-23-007302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007302/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007302
- JSON: https://secwatch.observer/filing/0001683168-23-007302.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007302.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. amended Warrant Agent Agreement with Equiniti Trust Company valued at Amendment to Warrant Agent Agreement reducing exercise price to $0.11 and eliminating prohibition on (effective 2023-10-18).
  - Action: amendment
  - Counterparty: Equiniti Trust Company
  - Value: Amendment to Warrant Agent Agreement reducing exercise price to $0.11 and eliminating prohibition on
  - Effective: 2023-10-18
  source text: On October 18, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an amendment to the Warrant Agent Agreement, dated February 17, 2022 (the “Warrant Agent Agreement”), between the Company and Equiniti Trust Company to (i) reduce the exercise price of the outstanding warrants issued by the Company on February 17, 2022 to $0.11, subject to further adjustment as provided therein, and (ii) eliminate the provision under the Warrant Agent Agreement that prohibits the Company’s chief executive officer, Dr. Steve N. Slilaty, from exercising his voting rights under his Series B Preferred Stock of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007302/0001683168-23-007302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.